Company profile
Sonnet BioTherapeutics
Powering a new wave of immune therapeutics
- Industry
- Biotechnology
- Employees
- 11
- Headquarters
- Princeton, NJ
- Founded
- 2011
- LinkedIn followers
- 2,408
- Office locations
- 1
Sonnet BioTherapeutics company summary
Sonnet BioTherapeutics is a company in the Biotechnology industry, headquartered in Princeton, NJ, founded in 2011. On LinkedIn the company has around 11 employees and 2,408 followers. Its listed specialties include Oncology, immunotherapy, biotherapeutics.
What technology does Sonnet BioTherapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Sonnet BioTherapeutics
As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process. (NASDAQ: SONN)
Specialties
Where is Sonnet BioTherapeutics located?
Sonnet BioTherapeutics lists 1 location.
Compare companies similar to Sonnet BioTherapeutics
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Sonnet BioTherapeutics sonnetbio.com | Biotechnology | 11 | 2011 | Princeton, NJ |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Sonnet BioTherapeutics
What does Sonnet BioTherapeutics do?
As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived therapeutic candidates, with our lead proprietary compound, SON-1010, in Phase 1 development. Closely following are SON-080, in Phase 1b/2a development, and three other candidates undergoing preclinical study. Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease. Sonnet’s FHAB construct attaches to albumin in the bloodstream, which significantly enhances the pharmacokinetics of the active drug substance. It also naturally accumulates at inflammation sites, including tumors, thereby potentiating delivery to target tissues. Our platform has demonstrated a tenfold increase in half-life and a greater-than-thirtyfold increase in efficacy as compared to recombinant interleukins without FHAB in preclinical studies. We believe the versatile platform can generate a large immune oncology pipeline, including combinations with a variety of biologic drugs. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence with a human glycosylation profile that can be manufactured using a standard CHO process. (NASDAQ: SONN)
How many employees does Sonnet BioTherapeutics have?
Sonnet BioTherapeutics has around 11 employees on LinkedIn.
Where is Sonnet BioTherapeutics headquartered?
Sonnet BioTherapeutics is headquartered in Princeton, NJ.
When was Sonnet BioTherapeutics founded?
Sonnet BioTherapeutics was founded in 2011.
Build a lead list from companies like Sonnet BioTherapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.